[{"id":"601f4c11-aa8c-4ff3-b9f2-91e657f67eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04481763","created_at":"2021-01-18T21:31:08.094Z","updated_at":"2024-07-02T16:36:42.869Z","phase":"Phase 1/2","brief_title":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","source_id_and_acronym":"NCT04481763","lead_sponsor":"Jiangxi Provincial Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 amplification • HER-2 negative • HER-2 amplification + PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 amplification • HER-2 negative • HER-2 amplification + PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/14/2020","start_date":" 07/14/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2020-07-22"}]